Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPemBra: pembrolizumab with intermittent/short-term dabrafenib + trametinib versus pembrolizumab alone in BRAF V600-mutant melanoma
NL-OMON47102Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, dabrafenib + trametinib and trametinib in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and feasibility and Immune activation in tumor and peripheral blood. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON47102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47102.